Apr 17, 2026
intoDNA Presents Data on Two Novel Assays, sSTRIDE-NER and sSTRIDE-PARP1, in Poster Presentations at the 2026 AACR Annual Meeting
Apr 17, 2026
intoDNA Presents Data on Two Novel Assays, sSTRIDE-NER and sSTRIDE-PARP1, in Poster Presentations at the 2026 AACR Annual Meeting
Mar 31, 2026
intoDNA to Present Two Poster Presentations at the 2026 AACR Annual Meeting
Feb 04, 2026
intoDNA Forms Strategic Advisory Board with Leading Diagnostics and Precision Oncology Experts
Jan 12, 2026
intoDNA Expands Leadership Team with Appointment of Maggie Rougier-Chapman as Chief Business Officer
Nov 25, 2025
intoDNA’s STRIDE™ named 2025 “Overall Genomics Innovation of the Year” by BioTech Breakthrough
Oct 15, 2025
New AstraZeneca Study Uses STRIDE™ to Reveal Synergistic Effects of ARPi and PARP Inhibitors in Prostate Cancer
Dec 09, 2024
intoDNA awarded funding through the European Funds for Smart Economy (FENG) under the “Ścieżka SMART” program
Feb 07, 2024
Magda Kordon-Kiszala speaks about the shortcomings of γH2AX at the DDR Inhibitors Summit 2024
Nov 17, 2023
STRIDE validated in human in vivo samples in collaboration with AstraZeneca
Nov 03, 2023
intoDNA exhibits at SITC 2023, the premier cancer immunotherapy conference
Jul 11, 2023
intoDNA to participate in the 2nd Annual Targeted Radiopharmaceuticals Summit US (TRP)
Mar 28, 2023
intoDNA to present and exhibit at the American Association for Cancer Research Annual Meeting 2023
Jul 19, 2022
intoDNA joins the BioInMed initiative gathering key medical biotechnology companies in Poland
Apr 28, 2022
Magda Kordon as an invited speaker at the DNA Repair/Replication Structures & Cancer Conference
Feb 24, 2022
Magda Kordon, CEO attending the 2022 Gordon Research Conference on DNA Damage, Mutation and Cancer
Sep 28, 2021